CRISPR Therapeutics has developed SyNTase editing, a proprietary, next-generation, site-specific gene correction platform.
A new study in Human Gene Therapy describes a machine learning (ML) model that can be used as a surrogate for laborious in vitro experiments. This in silico approach aims to increase the fitness of ...
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback